Latest news with #Vineland
Hans India
4 days ago
- Entertainment
- Hans India
Leonardo DiCaprio leads electrifying Paul Thomas Anderson thriller ‘One Battle After Another'
Warner Bros has dropped the explosive second official trailer for One Battle After Another, the upcoming action-packed political thriller from celebrated filmmaker Paul Thomas Anderson. Set to hit theatres on September 26, 2025, the film promises a gripping blend of high-stakes drama, unflinching action, and philosophical introspection, rooted in the ideologies of revolution and redemption. Drawing inspiration from Thomas Pynchon's cult postmodern novel Vineland (1990), One Battle After Another explores the aftermath of radical activism. The story follows a group of aging former revolutionaries who have long retreated into anonymity, only to be pulled back into conflict when their old enemy reappears after 16 years. With one of their own facing personal tragedy—a kidnapped daughter—they band together for one last mission, confronting not just their foe, but the bitter reckoning with their own beliefs and past betrayals. The film boasts a powerhouse ensemble including Leonardo DiCaprio, Regina Hall, Sean Penn, Alana Haim, Teyana Taylor, Wood Harris, Benicio del Toro, Shayna McHayle, and Chase Infiniti. Anderson, known for his distinctive blend of character-driven drama and visual stylization, infuses this political narrative with emotional weight and kinetic tension. The newly released trailer offers glimpses of explosive confrontations, covert operations, and a simmering ideological war—set against a stylized, almost surreal American backdrop. With its charged political undercurrent and themes of loyalty, disillusionment, and resistance, the film explores how far one will go to protect their principles—or bury them. Written and directed by Anderson, and produced alongside Sara Murphy and Adam Somner, One Battle After Another is shaping up to be one of 2025's most provocative cinematic offerings.
Geek Tyrant
5 days ago
- Entertainment
- Geek Tyrant
Thrilling and Fun New Trailer for Paul Thomas Anderson's ONE BATTLE AFTER ANOTHER — GeekTyrant
Warner Bros has released the second official trailer for Paul Thomas Anderson's upcoming film One Battle After Another , and it looks like Anderson's most action-driven project yet. The movie promises an intense blend of political intrigue and personal stakes. The story follows Bob Ferguson, played by Leonardo DiCaprio, a former revolutionary on a desperate mission to rescue his daughter after she's arrested. The official logline reads: 'When their evil enemy resurfaces after 16 years, a group of ex-revolutionaries reunites to rescue one of their own's daughter.' The movie is inspired by Thomas Pynchon's postmodern novel Vineland , and it feels like a gripping mix of Anderson's meticulous character work and explosive, large-scale action. The cast includes Regina Hall, Sean Penn, Alana Haim, Teyana Taylor, Wood Harris, Benicio del Toro as 'Sensei,' Shayna McHayle, and Chase Infiniti as Ferguson's daughter. The new trailer teases more character dynamics and escalating tension, all leading toward a high-stakes showdown between Bob and the feds. As one might expect from PTA, the visuals are rich with grit and atmosphere, and the tone hints at a slow-burn thriller that explodes into chaos when the moment comes. Watch the trailer below and get ready for what is sure to be a great film. One Battle After Another when it's released in theaters on September 26th.
Pink Villa
5 days ago
- Entertainment
- Pink Villa
One Battle After Another Trailer: Leonardo DiCaprio Impresses With His Revolutionary Look, Here's When The Film Will Release
The Warner Bros. Studio dropped the second trailer for One Battle After Another. The new preview gives the audience a glimpse at Leonardo DiCaprio's look as the former member of the revolutionary group, who goes on a search for his missing daughter. The upcoming film marks the director, Paul Thomas Anderson's, 10th feature film and his first collaboration with the Oscar-winning actor. According to the media reports, the film is likely to skip all of the fall film festivals due to the release date clash. However, the cinematic piece by the ace director could be premiered at Telluride. There has been no confirmation of the same yet. What to expect from One Battle After Another? As for the trailer of the DiCaprio starrer, One Battle After Another will see the actor playing the role of an ex-revolutionary member, Bob Ferguson. He heads out to find his missing daughter and hopes to get help from his fellow revolutionary group members. The movie is loosely based on Thomas Pynchon's Vineland and will dive deep into the father-daughter equation. The Titanic star is joined by Regina Hall, Teyana Taylor, Chase Infiniti, and Benicio del Toro to star in the action-packed movie. The trailer begins with DiCaprio's character revealing that he is creating a closed circuit and explaining that it is 'important to keep the cap shunted so you don't accidentally detonate the charge.' Further in the preview, the audience witnesses a group of people running through the fields with guns in their hands. In another scene, a pregnant woman also fires at the unknown, as Ferguson and his fellow mate sit back and clap. The first frame of the trailer itself hooks the audience to the screens, leaving them wanting more. The official synopsis of the film reads, 'A former member of a revolutionary group seeks help from other revolutionaries to find his missing daughter.' One Battle After Another is set to open in theaters on September 25, 2025.
Geek Tyrant
6 days ago
- Entertainment
- Geek Tyrant
Fantastic Trailers for Paul Thomas Anderson's ONE BATTLE AFTER ANOTHER Starring Leonardo DiCaprio — GeekTyrant
Two new trailers have been released for writer and director Paul Thomas Anderson's ( Punch-Drunk Love , There Will Be Blood , Licorice Pizza ) latest film, One Battle After Another . The film boasts an impressive cast that includes Leonardo DiCaprio, Regina Hall, Sean Penn, Alana Haim, Teyana Taylor, Wood Harris, Benicio del Toro, and Shayna McHayle. It has the feel of Taken , only grittier, as DiCaprio's character's daughter has been kidnapped, and he goes on the run to find her. One Battle After Another , formerly known as The Battle of Baktan Cross or Desert Highway or BC Project, is inspired by Thomas Pynchon's postmodern 1990 novel titled Vineland . The film's longline states, 'When their evil enemy resurfaces after 16 years, a group of ex-revolutionaries reunites to rescue one of their own's daughter.' This looks like it's going to be excellent. Check out the trailers below, and watch One Battle After Another when it's released in theatres on September 26th.
Business Wire
11-07-2025
- Health
- Business Wire
Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oak Hill Bio, a biotechnology company focused on developing life-changing therapies for people with rare diseases, today announced the publication in Nature Medicine of the results of the rugonersen Phase 1 TANGELO study in 1 to 12 year old children with Angelman syndrome.1 Oak Hill Bio recently obtained exclusive rights to rugonersen and plans to initiate a Phase 3 study in patients with Angelman syndrome in early 2026. The results published today (The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial, Hipp et al., Nature Medicine, DOI 10.1038/s41591-025-03784-7) showed adverse event rates for rugonersen consistent with other antisense oligonucleotides, the route of administration, and the patient population. The results also showed that treatment with rugonersen led to dose-dependent partial normalization of pathological brain activity on a pharmacodynamic biomarker of brain function, electroencephalogram (EEG) delta power, and improvements on multiple exploratory endpoints measuring the core symptoms of Angelman syndrome as compared to natural history. The safety and tolerability profile, as well as the encouraging pharmacodynamic and exploratory clinical effects observed in TANGELO, provide strong support for further testing of rugonersen for the treatment of Angelman syndrome. 'These promising results further support our decision to license exclusive rights to rugonersen. We are proud to support the continued development of this potential new treatment option," said Josh Distler, CEO of Oak Hill Bio. Share Angelman syndrome is caused by lack of the protein UBE3A in neurons due to a genetic defect on the maternal allele. UBE3A is expressed only from the maternal allele in neurons, while the paternal allele is silenced (imprinted) by a long non-coding antisense transcript (UBE3A-ATS) that interferes with the transcription of UBE3A from the paternal allele. Rugonersen (OHB-724) is designed to restore expression of UBE3A by suppressing the UBE3A-ATS transcript, thereby leveraging the intact paternal allele. TANGELO was a Phase 1, multicenter, open-label, multiple ascending, intra-patient dose escalation study that enrolled 61 patients aged 1-12 years with Angelman syndrome (mutation and deletion genotypes). In TANGELO, rugonersen led to a dose-dependent reduction in EEG delta power—a biomarker of abnormal brain activity in Angelman syndrome that has been shown to correlate with functional outcomes. The dynamics of the EEG biomarker provide robust pharmacodynamic data to inform the dose regimen of the planned Phase 3 trial. Exploratory clinical efficacy on developmental skills was assessed using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), and the Vineland Adaptive Behavior Scales, Third Edition (Vineland). Four out of five behavioral domains tested by the Bayley-III and all five of the Vineland domains analyzed showed developmental gains above expectations from natural history. Of these results, most gains in developmental ability approached or surpassed thresholds for minimal clinically important group differences. 'These are promising results that mark a major milestone in the development of disease-modifying therapies for Angelman syndrome,' said Dr. Mark Shen, Assistant Professor of Neuroscience and Psychiatry at the University of North Carolina School of Medicine and one of the principal investigators and authors of the paper. 'In this paper, we have shown that an investigational treatment targeting the root cause of a genetic neurodevelopmental disorder can improve both brain activity and behavioral symptoms as compared to natural history in a consistent and measurable way.' 'Although these results are exploratory, rugonersen shows promise based upon the evidence published today of improvements in both a neurophysiologic biomarker and functional endpoints in individuals with Angelman syndrome,' said Dr. Wen-Hann Tan, Attending Physician, Division of Genetics and Genomics at Boston Children's Hospital and Associate Professor of Pediatrics at Harvard Medical School, an expert on Angelman syndrome, who was not involved in the study. 'These results provide support for further investigation of rugonersen and UBE3A-targeting strategies in randomized controlled trials and highlight the potential value of EEG as a biomarker.' Angelman syndrome affects an estimated 500,000 individuals worldwide. It typically presents during early childhood and is characterized by cognitive and developmental issues, including speech and communication difficulties, motor impairment, balance issues, and debilitating seizures. Rugonersen was generally well tolerated across more than 450 intrathecal administrations among 61 participants, some of whom received treatment for up to four years. The most common adverse events (AEs) were transient pyrexia and vomiting, typically occurring shortly after dosing. Serious adverse events (SAEs) were experienced by 34% of participants and those deemed related to treatment occurred in 13% of participants (or 2% of administrations). Treatment-related SAEs included seizure, epilepsy, vomiting, pyrexia and post-lumbar puncture syndrome. No participants were withdrawn from the study due to AEs. 'These promising results further support our decision to license exclusive rights to rugonersen. We are proud to support the continued development of this potential new treatment option and are deeply appreciative of the patients, families, and investigators whose commitment made this work possible,' said Josh Distler, Chief Executive Officer of Oak Hill Bio. 'This publication in Nature Medicine reflects the strength of the science and the importance of advancing treatments that can meaningfully improve the lives of people living with Angelman syndrome and their families.' About Oak Hill Bio Oak Hill Bio is a clinical-stage biotechnology company dedicated to developing life-changing therapies for people with rare diseases. Its pipeline includes late-stage programs in Angelman syndrome and complications of extreme prematurity, as well as a preclinical asset for diabetic macular edema. For more information, visit _________________________ 1 This study was sponsored and conducted by Roche. Expand
